Higher activation of the interferon-gamma signaling pathway in systemic lupus erythematosus patients with a high type I IFN score: relation to disease activity

Clinical Rheumatology
Manman LiuXinfang Huang

Abstract

Increased IFN-γ levels have been associated with systemic lupus erythematosus (SLE). However, the relationships among IFN-γ, type I interferons (IFNs) and clinical features have not been extensively studied. Peripheral blood samples from 44 SLE patients and 36 healthy donors (HDs) were collected. Quantitative real-time PCR was used to assess the mRNA expression of IFNG, type II IFN-inducible genes (IRF1, GBP1, CXCL9, CXCL10, and SERPING1, which are used for the type II IFN score), type I IFN-inducible genes (IRF7, MX1, ISG15, and ISG20, which are used for the type I IFN score), TBX21, and EOMES in peripheral blood mononuclear cells. Flow cytometry was used to measure the IFN-γ levels in lymphocytes. The mRNA levels of type II IFN-inducible genes, IFNG, TBX21, and EOMES were significantly higher in SLE patients than those in HDs. Similarly, the percentages of IFN-γ-producing cells in lymphocytes and their subsets in SLE patients were significantly increased. Linear regression indicated that IFNG expression levels and type II IFN scores were positively correlated with anti-double-stranded DNA autoantibody levels and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores. Compared with patients with low type I IFN sco...Continue Reading

References

Nov 1, 1982·Arthritis and Rheumatism·E M TanR J Winchester
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Oct 4, 2003·Journal of Leukocyte Biology·Kate SchroderDavid A Hume
Dec 14, 2004·Arthritis and Rheumatism·Kyriakos A KirouMary K Crow
Jul 22, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Masayoshi HarigaiNobuyuki Miyasaka
Nov 19, 2009·Annals of the Rheumatic Diseases·Kwangwoo KimSang-Cheol Bae
Jan 14, 2011·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Paul HertzogShamith Samarajiwa
May 25, 2011·Proceedings of the National Academy of Sciences of the United States of America·Sandip BhattacharyyaLouis J Muglia
Jun 19, 2013·International Reviews of Immunology·Laurens P Kil, Rudi W Hendriks
Jul 11, 2013·Nature Reviews. Rheumatology·George K BertsiasDimitrios T Boumpas
Dec 18, 2013·Rheumatology·Bernard R LauwerysFrédéric A Houssiau
May 27, 2014·Frontiers in Immunology·James J KnoxLaura M McLane
Oct 22, 2016·International Immunopharmacology·Shuaihantian LuoQianjin Lu
Apr 5, 2017·Rheumatology·Olga ZharkovaLaurie S Davis

❮ Previous
Next ❯

Citations

Jul 24, 2020·Cancer Immunology, Immunotherapy : CII·Yanbin LiuHaihe Wang
May 7, 2020·Rheumatology·Jenna L ThomasonAnd Grant Hughes
Feb 1, 2021·Auto- Immunity Highlights·Meisam GachpazanMeysam Moghbeli
Oct 31, 2020·BioMed Research International·Wenping LiuJibo Wang
Dec 29, 2020·Seminars in Arthritis and Rheumatism·Wietske M LambersKarina de Leeuw
Mar 16, 2021·Frontiers in Immunology·Umut Can KucuksezerGunnur Deniz
Jul 4, 2021·Rheumatic Diseases Clinics of North America·Sirisha SirobhushanamJ Michelle Kahlenberg
Jul 13, 2021·Cytokine·Soudeh Ghafouri-FardAlireza Salimi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Fate Conversion By mRNA

mRNA-based technology is being studied as a potential technology that could be used to reprogram cell fate. This technique provides the potential to generate safe reprogrammed cells that can be used for clinical applications. Here is the latest research on cell fate conversion by mRNA.